Medpace Holdings, Inc. $MEDP Stake Boosted by Wasatch Advisors LP

Wasatch Advisors LP increased its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 19.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 773,931 shares of the company’s stock after acquiring an additional 125,625 shares during the period. Medpace comprises about 2.5% of Wasatch Advisors LP’s investment portfolio, making the stock its 4th biggest holding. Wasatch Advisors LP owned 2.71% of Medpace worth $371,634,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of MEDP. J2 Capital Management Inc bought a new position in Medpace in the first quarter valued at about $521,000. Louisiana State Employees Retirement System bought a new stake in shares of Medpace during the 1st quarter valued at about $3,121,000. Global Financial Private Client LLC grew its stake in shares of Medpace by 20.4% during the 1st quarter. Global Financial Private Client LLC now owns 1,892 shares of the company’s stock valued at $909,000 after purchasing an additional 320 shares during the period. Blue Trust Inc. increased its position in shares of Medpace by 26.2% during the 1st quarter. Blue Trust Inc. now owns 645 shares of the company’s stock valued at $310,000 after purchasing an additional 134 shares during the last quarter. Finally, OP Asset Management Ltd purchased a new stake in shares of Medpace during the 1st quarter valued at about $1,785,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on MEDP shares. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Barclays cut their target price on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research report on Friday, April 24th. BMO Capital Markets reduced their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Royal Bank Of Canada decreased their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Finally, Robert W. Baird dropped their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $467.08.

Insider Buying and Selling

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. This trade represents a 44.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 20.50% of the stock is owned by company insiders.

Medpace Stock Performance

MEDP stock opened at $527.07 on Friday. Medpace Holdings, Inc. has a one year low of $306.70 and a one year high of $628.92. The company’s fifty day moving average price is $451.19 and its 200-day moving average price is $497.02. The company has a market capitalization of $15.05 billion, a PE ratio of 33.13, a price-to-earnings-growth ratio of 2.64 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm’s revenue for the quarter was up 26.5% on a year-over-year basis. During the same period in the previous year, the business earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.